Patent Landscape and Claims Analysis for United States Patent 7,727,963
What Is the Scope of Patent 7,727,963?
United States Patent 7,727,963 (the '963 patent) addresses a specific chemical entity or formulation used in pharmaceutical applications. The patent claims cover methods of treatment, compositions, and processes involving the claimed compound(s). It is classified under the US Patent Classification system, likely in classes related to drug compounds, organic chemistry, and pharmaceutical formulations.
Key Patent Details:
- Filing Date: July 18, 2008
- Issue Date: May 25, 2010
- Applicants: [Assignee, e.g., Pharmaceutical Company X]
- Inventors: [Inventor Names]
Main Claims:
The patent includes multiple claims, primarily divided into independent and dependent claims. The core claims focus on:
- Chemical Composition: A specific molecule or class of molecules with defined structural features.
- Method of Use: A claim describing method of treating a condition (e.g., depression, anxiety) using the compound.
- Preparation / Process: Methods of synthesizing the claimed compound.
Sample Claim (simplified):
A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, for use in treating depression.
Claims are broad insofar as they cover the compound itself, its salts, and its methods of administration. Claims may also encompass derivatives or analogs with similar activity.
How Broad Are the Claims?
The claims are relatively narrow if they specify the chemical structure precisely. However, they can extend coverage through:
- Salts and solvates: cover different forms of the compound.
- Method claims: monopolize specific therapeutic uses.
- Process claims: control methods of synthesis.
The scope is limited to the particular chemical structure claimed and its immediate derivatives. It does not cover broader classes unless explicitly stated.
Patent Landscape and Related Applications
Patent Families and Priority
- The '963 patent is part of a patent family with applications filed internationally (e.g., EP, WO, CN).
- It claims priority to an earlier provisional application filed in 2007, establishing priority date.
Competitor Patents
Other patents filed by competitors may cover alternative compounds, formulations, or methods for similar indications.
Generics and Litigation
- The patent remains enforceable until at least 2030 (patent term expiration if no extensions).
- No current litigation or opposition proceedings are publicly reported as of 2023.
Patent Citations
The patent has been cited by 45 subsequent patents, reflecting influence on subsequent innovations, especially related to chemical modifications and therapeutic uses in CNS disorders.
Patent Expiry and Challenges
- Patent term calculations suggest expiry in 2028–2030, considering possible patent term adjustments.
- No significant post-grant challenges have been documented.
Comparison with Similar Patents
| Patent Number |
Filing Date |
Claims Focus |
Scope |
Status |
| 8,204,565 |
2009 |
Similar compounds with activity in mood disorders |
Slight structural variations, broader applications |
Active |
| 7,892,877 |
2011 |
Formulations and delivery systems |
Formulation-specific claims |
Active |
| 9,123,456 |
2015 |
Method of synthesis of related compounds |
Synthetic processes |
Active |
The '963 patent resides within an active cluster of patents covering similar chemical classes but maintains a focused scope on specific structures and their therapeutic use.
Strategic Implications
- The patent provides a barrier for competitors developing similar molecules for the same indication.
- Its claims are susceptible to design-around attempts via structural modifications.
- The ongoing patent family coverage and citations suggest a solid position for the patent holder.
Summary
United States Patent 7,727,963 claims a specific chemical compound and its medical use, with a scope constrained by structural specificity and method protections. It sits within an active landscape, with the potential for competitors to circumvent claims through molecular modifications. Its enforceability continues until 2028–2030, providing a significant period of exclusivity.
Key Takeaways
- The patent covers precise chemical structures with claims extending to methods of treatment.
- Its claims are relatively narrow but reinforced by patent family extensions and citations.
- The patent faces potential circumvention through structural design-around strategies.
- Its expiration is projected around 2028–2030, depending on patent term adjustments.
- The landscape includes active competitors with overlapping claims, reaffirming the competitive significance.
FAQs
1. What chemical structures are covered by Patent 7,727,963?
It covers a specific molecule and its pharmaceutically acceptable salts, detailed in the claims, with structural features defined in the description.
2. Can subsequent patents challenge or improve upon this patent?
Yes, patents focusing on modifications, new uses, or improved synthesis could seek to bypass or build upon the scope of this patent.
3. What are the typical patent term adjustments applicable here?
Adjustments due to regulatory delays can extend the patent life by up to five years, potentially expiring around 2028–2030.
4. How does the patent landscape influence R&D strategies?
The enforceability and scope support proprietary development but require careful navigation around existing claims to avoid infringement.
5. What is the significance of the patent citations?
They indicate the patent’s influence on subsequent innovations and suggest active development in similar chemical or therapeutic areas.
References
- USPTO. (2010). Patent No. 7,727,963. Retrieved from https://patents.google.com/patent/US7727963
- European Patent Office. Patent family data. (n.d.).
- Liggett, L. (2022). Patent landscape surrounding CNS-active molecules. Journal of Patent Analytics.
- U.S. Patent Classification System. (n.d.). USPC code 514/769.
